Sign in
WithdrawnNo phase

Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease

Key facts

Who runs it
Henan Institute of Cardiovascular Epidemiology
Trial code
Status
Withdrawn
Started
30 Dec 2024
Expected to end
30 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Indobufen
  • Aspirin
Record updated
20 November 2024
Why it stopped
shortage of funds

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • 18 years < age ≤ 85 years
  • Patients with confirmed stable coronary heart disease (must meet at least one of the following conditions); 2.1 a stenosis confirmed by Coronary angiography or dual-source CT, but the stenosis of the Left Main Artery (LMA) diameter is less than 50%, the stenosis of the left anterior descending branch(LAD)is less than 70%, and the stenosis of the two or three coronary arteries diameter is less than 70%, patient has no corresponding evidence of ischemia; 2.2 Patients after percutaneous coronary intervention (PCI): Dual antiplatelet therapy (DAPT) time is greater than 9 months, without cardiovascular events and ischemic symptoms; and currently receiving aspirin 100 mg/d with clopidogrel 75 mg/d or ticagrelor 90mg (bid) dual antiplatelet therapy; 2.3 Patients after coronary artery bypass graft (CABG): Dual antiplatelet therapy (DAPT) time is greater than 9 months, without cardiovascular events and ischemic symptoms; and currently receiving aspirin 100 mg/d with clopidogrel 75 mg/d or ticagrelor 90mg (bid) dual antiplatelet therapy
  • Willing to sign the informed consent

Who cannot take part

  • Acute coronary syndrome (ACS) occurred within 3 months before screening
  • Percutaneous coronary intervention or CABG surgery within 9 months before screening
  • Use of non-steroidal anti-inflammatory drugs (within 3 months)
  • Any other conditions (such as atrial fibrillation, pulmonary embolism, lower extremity venous thrombosis, artificial heart valve, etc.) who need oral or intravenous anticoagulation treatment
  • A positive history of Chronic Obstructive Pulmonary Disease (COPD)
  • bleeding tendency or severe lung disease
  • Active pathological bleeding
  • History of intracranial hemorrhage (less than 3 months)
  • Allergic to indobufen / aspirin (or any of its ingredients)
  • Have a history of drug or alcohol abuse in the past 2 years
  • In the past 3 months, the Arachidonic acid-induced platelet aggregation rate≥ 50%; inhibition rate ≤ 20% in the aspirin combined with clopidogrel treated patients
  • Congestive heart failure or left ventricular ejection fraction <35%
  • Severe liver injury (transaminases exceeding the upper limit of 2 times and above)
  • Hematological diseases, platelet count <100000 / mm3 or hemoglobin <10g / dL
  • Creatinine clearance <30ml/min
  • Pregnancy, lactation and those who have a birth plan

About the trial

What the trial wants to find out

This study evaluates the effect of Indobufen and Aspirin on platelet aggregation and long term prognosis in patients with stable coronary heart disease.

The 2 groups in the trial

  • IndobufenTreatment being tested

    200 mg Indobufen, bid po, 90 days

  • AspirinExisting treatment, for comparison

    100 mg Aspirin, qd po, 90 days

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Stable Coronary Heart Disease. A Prospective, Randomized and Controlled,Single Blind, Single-center, Opening Study
Record updated
20 November 2024